Drug Research
Novel Research Says Actin A Key Source of Spreading Cancer
The University of Freiburg researchers have found out that the release of prometastatic factors is influenced by the skeleton of the cell, known as actin.
As per a research team that was led by Dr. Robert Grosse and Dr. Carsten...
Drug Research
Genomic Ties Announced By UK With Thailand On Health Issues
A new partnership with Thailand to share the expertise of genome sequencing, research collaboration, education and training opportunities, as well as genomics data handling will help UK patients.
A MoU has been inked between deputy Prime Minister of Thailand, Anutin...
News
Digital media and ROI in Pharma
There was a pin-drop silence in the conference room. A senior executive from a multinational pharma company had asked me a question; “Which digital platform do you think is the best?”
His US headquartered boss wanted him to prioritize digital...
Drug Research
South Korean Pharma Sector Attracts Despite Drug Nod Delays
According to a survey from Fitch Solutions, South Korea's pharmaceutical market attractiveness is expected to stay strong despite ongoing concerns about the country's slow pace of drug authorizations.
According to the analysis, the pharmaceutical business will remain competitive due to...
News
From February 13, FDA In-Person Session To Start Barring Few
FDA has recently announced that it is going to restart its in-person meetings that are face-to-face beginning February 13 with industry sponsors of biologics and drugs. This step is taken after a shift took place toward all virtual meetings...
Drug Research
To Curb Medicine Inequality, 3-Year Novel Strategy Announced
A novel strategy for 2023–25 adopted by the Medicines Patent Pool looks to lessen the inequalities in access by way of enhancing the affordability as well as availability of health products across low- and-middle-income countries (LMIC).
The MPP which is...
Drug Research
EC approves Regeneron-Sanofi’s Dupixent for eosinophilic esophagitis
The European Commission (EC) has granted marketing authorisation for Regeneron Pharmaceuticals and Sanofi’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE).
Dupixent’s expanded authorisation in the European Union (EU) is intended to treat 12 years and older patients with EoE, who...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read